期刊文献+

狼疮肾炎患者治疗方案与病理分型关系的探讨 被引量:4

狼疮肾炎患者治疗方案与病理分型关系的探讨
暂未订购
导出
摘要 目的探讨狼疮肾炎(lupus nephritis,LN)患者治疗方案与病理分型的关系。方法选取2006年~2011年期间怀化医专附属怀化市第三人民医院收治的49例系统性红斑狼疮(systemic lupus erythematosus,SLE)伴肾损害的患者,均行肾活检证实为LN。分析病理类型,比较予肾上腺皮质激素(激素)联合免疫抑制剂治疗前后的临床指标。结果肾活检结果分别为Ⅰ型3例、Ⅱ型8例、Ⅲ型6例、Ⅳ型17例、Ⅴ型11例、Ⅵ型4例。对比每组中治疗前后的血尿素氮、血肌酐、血沉、血清C3、尿蛋白量五项临床指标均有统计学意义(P值分别为0.022,0.031,0.005,0.000,0.014);对比各组之间治疗后的血尿素氮、血肌酐、血沉、血清C3、尿蛋白量五项临床指标均无统计学意义(P>0.05)。结论 LN的病理类型以Ⅳ型和Ⅴ型居多。三组的治疗效果相当,可见激素联合免疫抑制剂对各型LN的治疗效果良好。 Objective To investigate the relationship between therapy and pathological type of lupus nephritis patients. Methods Totally 49 SLE patients with renal damage in our hospital from 2006 to 2011 were selected. All were proven LN after renal biopsy. Analyze the pathological type and the change of clinical indicators after the treatment of adrenal cortical hormone combined with Immunosuppressant. Results There were 3 cases oftype Ⅰ, 8 cases of type Ⅱ,6 cases of type Ⅲ, 17 cases of type Ⅳ, 11 cases of type Ⅴ, 4 cases of Ⅵ. Compared with the clinical indicators of each group before and after treatment, there were significant differences (P〈0.05).However, there was no significant difference in the clinical indicators after treatment between each group(P〉0.05). Gonclusion Most of the pathological type of LN are type Ⅵ and type V .The curative effect of three group are similar. The curative effect of adrenal cortical hormone combined with Immunosuppressant for LN is fine.
出处 《当代医学》 2013年第10期33-35,共3页 Contemporary Medicine
关键词 狼疮肾炎 治疗 病理 Lupus nephritis Therapy Pathology
  • 相关文献

参考文献11

二级参考文献23

  • 1李晓,陈楠,任红,陈晓农,张文,徐耀文,江永娣.153例狼疮性肾炎并发感染分析[J].上海第二医科大学学报,2005,25(3):319-320. 被引量:2
  • 2王禹,王树杰,王力宁.狼疮性肾炎临床表现与病理改变的关系[J].中国医科大学学报,2006,35(4):408-409. 被引量:4
  • 3Reveille JD.Predictive value of autoantibodies for activity of systemic lupus erythematosus[J].Lupus,2003,12(11):833-837.
  • 4Ruiz-Lrastor-za G, Khamashta MA, Castellino, et al, Systemic Lupus erythernatosus [J]. Lancet,2001,357:1027.
  • 5Briner & Rector. The Kidney [M]. 6th ed. Philadelphia:Saunders, 1999. 1350.
  • 6Adler SG, Cohen AH, Glassoek RS. Secondary glornemlar disease. In: Brenner BM(ed). The kidney [M]. 5th ed. Philadelphia WB Saunders, 1996. 1498 - 1516.
  • 7Austin HA. Therapy of Lupus nephritis, controlled trial of prednisone and cytotoxic drugs [J]. New EngJ Med,1986,314:614- 619.
  • 8Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis [ J ]. Semin Arthritis Rheum,2000,29(5) :321 - 327.
  • 9Euler HH, Schroeder JO, Harten P, et al. Treatment-Free remisson in severe system lupus erythematosus following Synchronization of plasmaphersis with subsequent pulse yclophamide [J ]. Arthritis Rheum, 1994,37 : 1784.
  • 10Wallace DJ, Goldfinger D, Pepkowitz SH, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide aphersis for proliferative lupus nephritis [J ]. J Clin Aphersis, 1998,13(4) : 163 - 166.

共引文献64

同被引文献37

  • 1Takeuchi T, Aoki K, Koide J, et al. Systemic lupus erythematosus with necrotizing vasculitis and upregulated expression of VLA-4 anti- gen [ J ]. Clin Rheumatol, 2009,14 ( 3 ) :370-374,.
  • 2Srivastava A, Pastor-Pareja JC, Igaki T, et al. Basement membrane remodeling is essential for Drosophila disc eversion and tumor inva- sion[ J]. Proc Natl Aead Sei US A ,2007,104 (8) :2721-2726.
  • 3Saren P, Welgus HG, Kovanen Fr. TNF-alpha and IL-1 beta selec- tively induce expression of 92-kDa gelatinase by human macrophages [ J]. J Immunol,2006,157 (9) :4159-4165.
  • 4Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of ma- trix metalloproteinases in systemic lupus erythematosus with central nervous system engagement . Arthritis Res Ther, 2004,6 ( 6 ) : 551-556.
  • 5Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to lefluno- rnide but not to dexamethasone favors the production by monocytic cells of interlenkin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 beta and metalloprotei- nases [ J ]. Eur Cytokine Netw ,2008 ,9 (4) :663-668.
  • 6Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus[J]. Lancet, 2001,357(9261) : 1027-1032.
  • 7Bertsias GK,Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association ( EULAR/ERA-EDTA ) recommendations for the management of adult and aediatrie lupus nephritis[J]. Ann Rheum Dis,2012,71(ll) :1771-1782.
  • 8Yap DY, Ma MK, Tang CS, et al. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience[J]. Nephrology(Carlton) ,2012,17(8) :676-680.
  • 9邱英,陈翔,鲁慧,匡叶红,粟娟,吴丽莎.CD147与P糖蛋白在SLE患者外周血单一核细胞表达[J].中华皮肤科杂志,2010,43(1):52-53. 被引量:1
  • 10宁娟.糖皮质激素联合环磷酰胺治疗狼疮肾炎的临床分析[J].中国医师进修杂志,2011,34(34):52-53. 被引量:3

引证文献4

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部